-
公开(公告)号：US20240293361A1
公开(公告)日：2024-09-05
申请号：US17791239
申请日：2021-01-25
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
IPC分类号： A61K31/40 , A61K33/243 , A61P27/16
CPC分类号： A61K31/40 , A61P27/16 , A61K33/243
摘要： The invention relates to methods and compositions for treating or preventing drug-induced hearing loss.
-
2.发明公开公开(公告)号：US20240238339A1
公开(公告)日：2024-07-18
申请号：US18425487
申请日：2024-01-29
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
摘要： Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.
-
公开(公告)号：US20240189351A1
公开(公告)日：2024-06-13
申请号：US18285218
申请日：2022-04-01
申请人： The United States of America, as represented by the Secretary, Dept.of Health and Human Services
发明人： Raj K. Puri , Bharatkumar H. Joshi
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464419 , A61K45/06 , A61P35/00 , C07K16/2866 , C12N5/0636 , C12N15/86 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/22 , C12N2740/15043
摘要： Immunotherapies, particularly chimeric antigen receptors targeting IL-13Rα2 and their use for treating cancer are provided. A single chain fragment variable (scFv) that specifically binds IL-13Rα2, chimeric antigen receptors (CARs) including the IL-13Rα2 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Also provided are methods of treating a subject with cancer, including administering to the subject an immune cell expressing an IL-13Rα2 scFv-CAR alone or in combination with other cancer therapies.
-
公开(公告)号：US20240124468A1
公开(公告)日：2024-04-18
申请号：US18257746
申请日：2021-12-15
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , The United States of America, as Represented by the Secretary, Dept. of Health and Human Services , KUROME THERAPEUTICS, INC.
发明人： Scott Bryan HOYT , Craig Joseph THOMAS , Daniel T. STARCZYNOWSKI , Patrick Joseph SUTTER , Gregory James TAWA , Chris James FINOCCHIO , Jan Susan ROSENBAUM , Gabriel GRACIA MALDONADO
IPC分类号： C07D487/04 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/635 , A61P35/02 , C07D519/00
CPC分类号： C07D487/04 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/635 , A61P35/02 , C07D519/00
摘要： Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
-
5.发明公开公开(公告)号：US20240109955A1
公开(公告)日：2024-04-04
申请号：US18345478
申请日：2023-06-30
申请人： ModeX Therapeutics, Inc. , The United States of America, As Represented by the Secretary, Dept. of Health and Human Services
发明人： Juan LI , Chi-Jen WEI , Ronnie R. WEI , Zhi-Yong YANG , John R. MASCOLA , Gary J. NABEL , John MISASI , Amarendra PEGU , Lingshu WANG , Tongqing ZHOU , Misook CHOE , Olamide K. OLONINIYI , Bingchun ZHAO , Yi ZHANG , Eun Sung YANG , Man CHEN , Kwanyee LEUNG , Wei SHI , Nancy J. SULLIVAN , Peter D. KWONG , Richard A. KOUP , Barney S. GRAHAM , Peng HE
IPC分类号： C07K16/10 , A61P31/14 , G01N33/569
CPC分类号： C07K16/1003 , A61P31/14 , G01N33/56983 , C07K2317/24 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/92
摘要： Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.
-
公开(公告)号：US20230089654A1
公开(公告)日：2023-03-23
申请号：US17821703
申请日：2022-08-23
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
摘要： Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.
-
公开(公告)号：US20220372525A1
公开(公告)日：2022-11-24
申请号：US17848563
申请日：2022-06-24
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , President and Fellows of Harvard College , Rutgers, The State University of New Jersey , Skolkovo Institute of Science and Technology , The United States of America, as represented by the Secretary, Dept. of Health and Human Services
发明人： Konstantin Severinov , Feng Zhang , Yuri I. Wolf , Sergey Shmakov , Ekaterina Semenova , Leonid Minakhin , Kira S. Makarova , Eugene Koonin , Silvana Konermann , Julia Joung , Jonathan S. Gootenberg , Omar O. Abudayyeh , Eric S. Lander
IPC分类号： C12N15/90 , C12N15/10 , C12N15/63 , C12N9/22 , C12N15/11 , C12N15/82 , C12N15/85 , C12N15/113
摘要： The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
-
公开(公告)号：US20220313680A1
公开(公告)日：2022-10-06
申请号：US17706461
申请日：2022-03-28
申请人： Duke University , The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
发明人： Nicole Calakos , Zachary F. Caffall , Joseph Rittiner , Min Shen , Jennifer T. Fox , Zhuyin Li
IPC分类号： A61K31/47 , C12Q1/6883 , G01N33/68 , C12Q1/68 , A61K31/17 , A61K31/4706 , A61P25/14 , A61K31/4725 , A61K38/05 , A61K31/427 , A61K31/472 , A61K31/497 , A61K31/513
摘要： The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.
-
公开(公告)号：US11434268B2
公开(公告)日：2022-09-06
申请号：US16051062
申请日：2018-07-31
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
发明人： Donald P. Bottaro , Fabiola Cecchi
IPC分类号： A61K38/18 , C07K14/475 , C07K14/52 , C07K14/71
摘要： The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
-
公开(公告)号：US20220184111A1
公开(公告)日：2022-06-16
申请号：US17682655
申请日：2022-02-28
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
IPC分类号： A61K31/713 , A61K31/704 , A61K31/52 , A61K31/137 , A61K31/365 , A61K31/65 , A61K31/706 , A61K39/395 , A61K31/711 , A61K31/7064 , A61K31/437 , A61K31/505 , A61K31/712 , C07K16/28 , A61P39/00 , A61K31/351 , A61K31/787 , A61P35/00 , A61K31/513 , A61K45/06
摘要： Disclosed herein are methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. Example disclosed methods reduce cardiotoxicity of a chemotherapeutic agent. Also disclosed are methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the chemotherapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
221 条记录 (耗时 0.049 秒)
